|
Synonyms: CA170_01519.g57 IgG4P | rozanolixizumab-noli | Rystiggo® | UCB-7665 | UCB7665
rozanolixizumab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Rozanolixizumab is an anti-human FcRn monoclonal antibody that is being developed for potential use in the treatment of IgG-driven autoimmune diseases [1,3-4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Finney HM, Lawson ADG, Shaw SG, Smith BJ, Tyson KL, Kevorkian L. (2014)
Anti-fcrn antibodies. Patent number: WO2014019727. Assignee: Ucb Pharma S.A.. Priority date: 14/05/2012. Publication date: 06/02/2014. |
|
2. Hoy SM. (2023)
Rozanolixizumab: First Approval. Drugs, 83 (14): 1341-1347. [PMID:37656420] |
|
3. Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, Christodoulou L, Jones E, Price G, Smith B et al.. (2017)
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Sci Transl Med, 9 (414). [PMID:29093180] |
|
4. Zhu LN, Hou HM, Wang S, Zhang S, Wang GG, Guo ZY, Wu J. (2023)
FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res, 18 (8): 1637-1644. [PMID:36751773] |
